Curia

At Curia, we’re passionate about bringing your large molecule projects to life with our end-to-end solutions! Stop by booth 816, we’d love to chat about Discovery, Cell Line Development, Process & Analytical Development, Tox Manufacturing, and GMP Manufacturing. See you there! https://ow.ly/Ypgp50V67HE #BPIWest #Curia

Breaking: Curia today announced expansion plans to its Glasgow, UK facility and provided updates on the ongoing expansion in Albuquerque, NM. The Glasgow expansion will further strengthen Curia’s offering of sterile injectable product development from pre-formulation, through the clinical phases and commercial manufacturing. This is in addition to a $200 million investment in an ongoing, multi-year expansion project at Curia’s Albuquerque facility. >>> Learn more at: https://ow.ly/QKJ350Vj9A2 #globalnetwork #CDMO #fillfinish

Decades of Biopharma Manufacturing Excellence, Right Here in the U.S. Curia has a long-standing legacy of biopharma manufacturing in the U.S., and we’re thrilled to showcase our state-of-the-art facilities at the 2025 American Biomanufacturing Summit! Let’s connect to explore how Curia can help you: **Secure your supply chain, eliminate shipping and customs risks **Accelerate commercialization with our network of U.S. sites. **Tap into scientific expertise for process & formulation development, drug substance, and drug product manufacturing Schedule a meeting with us today: https://ow.ly/fVBk50Vi6Iv #Biomanufacturing #Curia #SupplyChain #PharmaInnovation

The countdown to #DCAT2025! Partnering with Curia means your pipeline is in expert hands. We're hard at work advancing your projects — from Curiosity to Cure! From Small Molecules to Generic APIs, Biologics, Sterile Fill-Finish, and Analytical Services — we’re your trusted ally every step of the way https://ow.ly/FRIG50Vgpxj #DCAT2025

#Breaking: Curia today announced it has refinanced its secured credit facilities. The transaction provides Curia with incremental capital and extends the maturities of its secured credit facilities, positioning the business for continued growth, allowing the company to capitalize on the attractive market opportunities in the drug development and manufacturing markets, and advancing its mission of partnering with biopharmaceutical customers to bring life-changing therapies to market. Curia's growth initiatives include significant investment expanding capabilities at its facilities in Rensselaer, New York, Albuquerque, New Mexico and Glasgow, UK. >>> Learn more at: https://lnkd.in/enUqP_pD

At Curia, we are proud to support International Women’s Day. We continue to #AccelerateAction toward women’s advancement and gender equality through our DE&I initiatives and support for women in STEM. In celebration of #IWD2025, Curia team members from all over the world shared what it means to accelerate action and emphasized the importance of urgent action to drive meaningful progress. #Internationalwomensday

Curia has a strong track record of getting APIs approved around the world, thanks to our expertise in navigating complex regulatory markets. Most recently, China approved one of our portfolio APIs, Betamethasone Dipropionate Micronized. This is yet another example of our commitment to delivering high-quality APIs and ensuring regulatory excellence on a global scale. Check out our API Catalog: https://ow.ly/vUBG50Vb39A #APIManufacturing #RegulatoryExcellence #CDMO

We’re thrilled to be exhibiting at Bioprocess International West! Stop by booth 816 to chat with our experts about manufacturing for mRNA and protein therapeutics. Let’s talk about how we can take your project from Curiosity to Cure! See you there! https://ow.ly/azhu50V6776 #Bioprocessing #Curia

At Curia, we are at the forefront of advancing novel conjugates, helping to accelerate the development of life-changing therapies through our cutting-edge technology, expertise, and commitment to quality. Together, we can unlock the potential of novel conjugates to create better, more targeted treatments for patients worldwide. Schedule time to meet with us, from Curiosity to Cure-Curia! https://ow.ly/3uA450V9jRE

#CuriaForRareDiseases: With over 6,000 identified rare diseases, millions of people face challenges in diagnosis and treatment. 1 in 5 cancers is rare, and 70% of rare diseases begin in childhood- yet treatment options remain limited. At Curia, we are dedicated to advancing solutions for rare diseases through API innovation, including offering Ganaxolone API for regulatory purposes. #Ganaxolone represents one of the many ways we’re supporting the development of therapies that can make a real difference in the lives of those affected. Because behind every rare disease statistic is a person, a family, and a story worth fighting for. Discover how Curia’s API capabilities, including Ganaxolone, are helping advance the treatment of rare diseases: https://ow.ly/rPs150V8oEB #APIInnovation #RareDiseaseResearch #Ganaxolone #FromCuriosityToCure